Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes

被引：14

作者：

Certikova Chabova, Vera ^{[1
]}

Zakiyanov, Oskar

机构：

[1] Charles Univ Prague, Fac Med 1, Dept Nephrol, U Nemocnice 2, Prague 12800 2, Czech Republic

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 05期

关键词：

SGLT2; inhibitors; diabetes; chronic kidney disease; heart failure; CHRONIC KIDNEY-DISEASE; SERUM URIC-ACID; BLOOD-PRESSURE; SGLT2; INHIBITORS; DOUBLE-BLIND; GLYCEMIC CONTROL; SECONDARY ANALYSIS; ADIPOSE-TISSUE; BODY-WEIGHT; FAT MASS;

D O I：

10.3390/ijms23052812

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Sodium glucose transporter type 2 (SGLT2) molecules are found in proximal tubules of the kidney, and perhaps in the brain or intestine, but rarely in any other tissue. However, their inhibitors, intended to improve diabetes compensation, have many more beneficial effects. They improve kidney and cardiovascular outcomes and decrease mortality. These benefits are not limited to diabetics but were also found in non-diabetic individuals. The pathophysiological pathways underlying the treatment success have been investigated in both clinical and experimental studies. There have been numerous excellent reviews, but these were mostly restricted to limited aspects of the knowledge. The aim of this review is to summarize the known experimental and clinical evidence of SGLT2 inhibitors' effects on individual organs (kidney, heart, liver, etc.), as well as the systemic changes that lead to an improvement in clinical outcomes.

引用

收藏

页数：17

相关论文

共 156 条

[1] Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes [J].

Aberle, Jens ;

Menzen, Markus ;

Schmid, Sebastian M. ;

Terkamp, Christoph ;

Jaeckel, Elmar ;

Rohwedder, Katja ;

Scheerer, Markus F. ;

Xu, John ;

Tang, Weifeng ;

Birkenfeld, Andreas L. .

SCIENTIFIC REPORTS, 2020, 10 (01)

[2] KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts [J].

不详 .

KIDNEY INTERNATIONAL, 2021, 99 (03) :S26-S87

[3] The effect of canagliflozin on amputation risk in theCANVASprogram and theCREDENCEtrial [J].

Arnott, Clare ;

Huang, Yuli ;

Neuen, Brendon L. ;

Di Tanna, Gian Luca ;

Cannon, Christopher P. ;

Oh, Richard ;

Edwards, Robert ;

Kavalam, Mary ;

Rosenthal, Norman ;

Perkovic, Vlado ;

Jardine, Meg J. ;

Mahaffey, Kenneth ;

Neal, Bruce .

DIABETES OBESITY & METABOLISM, 2020, 22 (10) :1753-1766

[4] Effects of Sodium-Glucose Cotransporter 2 Inhibitors on 24-Hour Ambulatory Blood Pressure: A Systematic Review and Meta-Analysis [J].

Baker, William L. ;

Buckley, Leo F. ;

Kelly, Michael S. ;

Bucheit, John D. ;

Parod, Eric D. ;

Brown, Roy ;

Carbone, Salvatore ;

Abbate, Antonio ;

Dixon, Dave L. .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (05)

[5] Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2 Subgroup Analysis of the Randomized CREDENCE Trial [J].

Bakris, George ;

Oshima, Megumi ;

Mahaffey, Kenneth W. ;

Agarwal, Rajiv ;

Cannon, Christopher P. ;

Capuano, George ;

Charytan, David M. ;

de Zeeuw, Dick ;

Edwards, Robert ;

Greene, Tom ;

Heerspink, Hiddo J. L. ;

Levin, Adeera ;

Neal, Bruce ;

Oh, Richard ;

Pollock, Carol ;

Rosenthal, Norman ;

Wheeler, David C. ;

Zhang, Hong ;

Zinman, Bernard ;

Jardine, Meg J. ;

Perkovic, Vlado .

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (12) :1705-1714

[6] Hypertension Treatment and Concern About Falling: Baseline Data from the Systolic Blood Pressure Intervention Trial [J].

Berlowitz, Dan R. ;

Breaux-Shropshire, Tonya ;

Foy, Capri G. ;

Gren, Lisa H. ;

Kazis, Lewis ;

Lerner, Alan J. ;

Newman, Jill C. ;

Powell, James R. ;

Riley, William T. ;

Rosman, Robert ;

Wadley, Virginia G. ;

Williams, Julie A. .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2016, 64 (11) :2302-2306

[7] Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin [J].

Bolinder, J. ;

Ljunggren, O. ;

Johansson, L. ;

Wilding, J. ;

Langkilde, A. M. ;

Sjostrom, C. D. ;

Sugg, J. ;

Parikh, S. .

DIABETES OBESITY & METABOLISM, 2014, 16 (02) :159-169

[8] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

[9] Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes [J].

Bolla, Andrea Mario ;

Butera, Elena ;

Pellegrini, Silvia ;

Caretto, Amelia ;

Bonfanti, Riccardo ;

Zuppardo, Raffaella Alessia ;

Barera, Graziano ;

Cavestro, Giulia Martina ;

Sordi, Valeria ;

Bosi, Emanuele .

ACTA DIABETOLOGICA, 2020, 57 (11) :1367-1373

[10] SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system [J].

Bonora, Benedetta Maria ;

Raschi, Emanuel ;

Avogaro, Angelo ;

Fadini, Gian Paolo .

CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)

← 1 2 3 4 5 6 7 8 9 10 →